$NPCE

NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026

NeuroPace, Inc. announced it will report its financial results for the fourth quarter of 2025 after market close on Tuesday, March 3, 2026. A conference call and webcast will follow at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) for investors to participate and listen to the discussion. The webcast will be archived on the company's investor relations website for replay.

Original reporting
Published Feb 20, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Feb 20, 2026, 10:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$NPCE
Bullish
medium confidence
Mentioned
$NPCE
Relevance
6/10
AlphAI data visualization · based on Business Wire
Decision brief

The 30-second read

$NPCEBullishMed
01

Why it matters

The upcoming earnings report is a key event that could influence stock price volatility.

02

Market read

The news is highly relevant for traders with short-term focus, especially around the earnings date.

03

What to watch

Potential regulatory hurdles or market-wide downturns could negate positive earnings impact.

Relevance 6/10Timing: High, as earnings report is scheduled for March 3, 2026.

Background

NeuroPace is a neurotechnology company focusing on implantable devices for neurological conditions.

Company-level read

Ticker impact

$NPCEBullishMedium confidence
Context

Primary focus due to upcoming earnings report and positive sentiment.

Expected impact

Moderate upward movement expected post-earnings, with potential for increased volatility around the event.

Evidence & confidence

Earnings reports often influence stock prices; the current sentiment indicates optimism. However, the 'somewhat bullish' sentiment and limited relevance score (1.0) suggest caution.

Market effects

Potential positive impact on the medical devices and life sciences sectors, especially companies involved in neurotechnology.

Limited, primarily affecting U.S. markets where NeuroPace operates.

Low, as NeuroPace is a specialized medical device company with limited global exposure.

Counterpoint

Earnings may underperform expectations, leading to a short-term decline despite positive sentiment.

Key entities

  • NeuroPace, Inc.

    Developer of implantable neurostimulation devices.

  • Earnings Report Q4 2025

    Financial results announcement scheduled for March 3, 2026.

Related articles

$NPCEMed

NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

NeuroPace Inc (NPCE) filed an SEC Form 8-K — Results of Operations and Financial Condition. NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance Q2 2026 total revenue of $22.8 million, including $22.5 million in RNS revenue representing 21% growth Raises full year 2026 total revenue guidance to $99.5 million to $101.5 million, which a

$JNJMed

Johnson & Johnson Reports Sustained Two-Year ICOTYDE Results In Plaque Psoriasis

Johnson & Johnson (JNJ) reported two-year results from its Phase 3 ICONIC-LEAD study of ICOTYDE for plaque psoriasis, showing sustained skin clearance and symptom improvements. At Week 112, 72% of patients achieved PASI 90, 70% had clear/almost clear skin, and 44% had complete clearance. Safety findings were consistent with the drug's profile. JNJ is also studying ICOTYDE for other conditions. JNJ closed at $256.48, down 0.76%, and was down 0.15% in premarket trading.

$MISTMed

Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial

Milestone Pharmaceuticals (MIST) announced the first European patient has been enrolled in its Phase 3 ReVeRA-301 trial for etripamil nasal spray to treat atrial fibrillation with rapid ventricular rate (AFib-RVR). The study, targeting 150 patients, is evaluating the same 70 mg dose approved for PSVT in the U.S. as CARDAMYST. Enrollment is ongoing in the U.S. and Canada.

$ALMSHighAI 9/10

Alumis Reports Positive Phase 3 Data With Envudeucitinib

Alumis (ALMS) reported Phase 3 data for envudeucitinib, showing a 54% PASI 100 response rate at Week 48. The company aims for a 2026 NDA submission. Shares rose 3.49% in pre-market trading to $7.21. According to the CEO, the results support its potential as a leading oral therapy for plaque psoriasis.